<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17430">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879981</url>
  </required_header>
  <id_info>
    <org_study_id>ML30017</org_study_id>
    <nct_id>NCT02879981</nct_id>
  </id_info>
  <brief_title>A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis</brief_title>
  <official_title>A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Pediatric Patients With Acute Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This pilot, multicentric and observational study will assess the of safety of
      sulfamethoxazole + trimethoprim + guaifenesin (Balsamic Bactrim) in pediatric participants
      with acute bronchitis. Administration of treatment will be according to physician's
      recommendation under local labeling.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">June 24, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Related Adverse Events to Sulfamethoxazole + Trimethoprim + Guaifenesin as Assessed by Physician</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Compliance to Prescribed Dosage Regimen, As Assessed by Physician in Accordance With Local Clinical Practice and Local Labeling</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Dose (Increase or Decrease) of Balsamic Bactrim</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reason for Change in Dose (Increase or Decrease) of Balsamic Bactrim</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change in Frequency of Balsamic Bactrim Dosing</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Predisposing Factors (Categories) for Safety (No specific predefined factors, these will be decided based on observations during study)</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Dose Interruptions</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Balsamic Bactrim Dose Reintroduction</measure>
    <time_frame>Baseline up to 5 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bronchitis</condition>
  <arm_group>
    <arm_group_label>Pediatric Participants With Acute Bronchitis</arm_group_label>
    <description>Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim (sulfamethoxazole + trimethoprim + guaifenesin) according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to sulfamethoxazole + trimethoprim + guaifenesin as per the local label will be observed for safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guaifenesin</intervention_name>
    <description>Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.</description>
    <arm_group_label>Pediatric Participants With Acute Bronchitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfamethoxazole</intervention_name>
    <description>Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.</description>
    <arm_group_label>Pediatric Participants With Acute Bronchitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.</description>
    <arm_group_label>Pediatric Participants With Acute Bronchitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim
        according to standard of care and in line with the current summary of product
        characteristics (SPC) / local labeling and who have no contraindication to Balsamic
        Bactrim as per the local label
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants starting treatment with Bactrim Balsamic suspension

          -  Participants with a clinical diagnosis of acute bronchitis according to the
             pulmonologist clinical criteria

        Exclusion Criteria:

          -  Participants who have started treatment with another antibiotic at the time of the
             visit

          -  Participants with no respiratory infections

          -  Participants with mental disorders

          -  Participants with severe hepatic parenchymal damage

          -  Participants with severe renal failure making it difficult to monitor drug plasma
             concentration

          -  Participants with hypersensitivity to any of Balsamic Bactrim active ingredients or
             excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML30017 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Emergencias Pediatricas; Unidad de Investigación Pediátrica</name>
      <address>
        <city>La Victoria</city>
        <zip>15033</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional</name>
      <address>
        <city>Lima</city>
        <zip>Lima 41</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Anglo Americana-CENTRO DE INVESTIGACION PEDIATRIA CAA</name>
      <address>
        <city>San Isidro</city>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>August 23, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
